KAZAN, Russian Federation,
April 1 /PRNewswire/ - Neuro-Biotech
Corp. (PinkSheets: MRES.pk - News) (OTCQB: MRES) and Auric Pharma
Science have accepted all terms and conditions and successfully
completed all due diligence requirements. Both companies have
agreed to complete the agreement on Tuesday
April 5 at its new corporate head office in Kazan,
Russian Federation.
Mr. Boris Oleknovich, CEO and
President of Neuro-Biotech Corp. commented: "Merging these two
incredible companies into one, can only lead to great things,
combining sales, research & development, distribution channels
and great scientific minds will make us a force to be reckoned
with. We would like to thank our shareholders for their loyalty and
to assure them that they will greatly benefit and profit from our
success."
"Mr. Oleknovich will remain President, I will assume the
position of CEO, together we will build a giant, We plan to open
manufacturing/production and distribution facilities in
North America in the near future."
stated Mr. Norman Hathaway,
President and CEO of Auric Pharma Science.
For more information on Neuro-Biotech Corp or to contact a
company representative, please visit:
www.neuro-biotechcorp.com.
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Act of
1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.